|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Tamura T: New state of the art in
small-cell lung cancer. Oncology (Williston Park). 15:8–10.
2001.
|
|
3
|
Khuder SA and Mutgi AB: Effect of smoking
cessation on major histologic types of lung cancer. Chest.
120:1577–1583. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kiyohara C, Shirakawa T and Hopkin JM:
Genetic polymorphism of enzymes involved in xenobiotic metabolism
and the risk of lung cancer. Env Health Prev Med. 7:47–59. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawajiri K, Nakachi K, Imai K, Watanabe J
and Hayashi S: The CYP1A1 gene and cancer susceptibility. Crit Rev
Oncol Hematol. 14:77–87. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benhamou S, Lee WJ, Alexandrie AK,
Boffetta P, Bouchardy C, Butkiewicz D, Brockmöller J, Clapper ML,
Daly A, Dolzan V, et al: Meta- and pooled analyses of the effects
of glutathione S-transferase M1 polymorphisms and smoking in lung
cancer risk. Carcinogenesis. 23:1343–1350. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye Z, Song H, Higgins JP, Pharoah P and
Danesh J: Five glutathione S-transferase gene variants in 23452
cases of lung cancer and 30397 controls: meta-analysis of 130
studies. PLoS Med. 3:912003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Denissenko M, Pao A, Tang MS and Pfeifer
GP: Preferential formation of benzo(a)pyrene adducts at lung cancer
mutational hotspots in p53. Science. 274:430–432. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wiencke J, Varkonyi A, Semey K, et al:
Detection of benzene-related DNA adducts in human tissues and
evidence of co-activation with polyaromatic hydrocarbons. Proc Am
Assoc Cancer Res. 36:1351995.
|
|
10
|
Kriek E, Van Shooten FJ, Hillebrand MJX,
Van Leeuwen FE, Den Engelse L, De Looff AJ and Dijkmans AP: DNA
adducts as a measure of lung cancer risk in human exposed to
polycyclic aromatic hydrocarbons. Env Health Perspect. 99:71–75.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bouchardy C, Benhamou S, Jourenkova N,
Dayer P and Hirvonen A: Metabolic genetic polymorphisms and
susceptibility to lung cancer. Lung Cancer. 32:109–112. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raunio H, Husgafvel-Pursianinen K, Anttila
S, Hietanen E, Hirvonen A and Pelkonen O: Diagnosis of
polymorphisms in carcinogen-activating and inactivating enzymes and
cancer susceptibility-a review. Gene. 159:113–121. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perera FP, Mooney LA, Stampfer M, Phillips
DH, Bell DA, Rundle A, Cho S, Tsai WY, Ma J, Blackwood A and Tang
D: Associations between carcinogen-DNA damage, glutathione
S-transferase genotypes and risk of lung cancer in the prospective
Physicians' Health Cohort Study. Carcinogenesis. 23:1641–1646.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar M, Agarwal SK and Goel SK: Lung
cancer risk in north Indian population: role of genetic
polymorphisms and smoking. Mol Cell Biochem. 322:73–79. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
San Jose C, Cabanillas A, Benitez J,
Carrillo JA, Jimenez M and Gervasini G: CYP1A1 gene polymorphisms
increase lung cancer risk in a high-incidence region of Spain: a
case-control study. BMC Cancer. 10:4632010.PubMed/NCBI
|
|
16
|
Sampaio AC, Morari EC, Bufalo NE, Leite
JL, Lima CS and Ward LS: Lack of influence of glutathione
S-transferase genotype profile on cancer susceptibility in smokers
and non-smokers. Med Sci Monit. 15:10–15. 2009.PubMed/NCBI
|
|
17
|
Bartsch H, Nair U, Risch A, Rojas M,
Wikman H and Alexandrov K: Genetic polymorphism of CYP genes, alone
or in combination, as a risk modifier of tobacco-related cancers.
Cancer Epidem Biom Prev. 9:3–28. 2000.PubMed/NCBI
|
|
18
|
Hung RJ, Boffetta P, Brockmoller J,
Butkiewicz D, Cascorbi I, Clapper ML, Garte S, Haugen A, Hirvonen
A, Anttila S, et al: CYP1A1 and GSTM1 genetic polymorphisms and
lung cancer risk in Caucasian non-smokers: a pooled analysis.
Carcinogenesis. 24:875–882. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cote ML, Chen W, Smith DW, Benhamou S,
Bouchardy C, Butkiewicz D, Fong KM, Gené M, Hirvonen A, Kiyohara C,
et al: Meta- and pooled analysis of GSTP1 polymorphism and lung
cancer: a HuGE-GSEC review. Am J Epidem. 169:802–814. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carlsten C, Saggo GS, Frodsham AJ, Burke W
and Higgins JP: Glutathione S-transferase M1 (GSTM1) polymorphisms
and lung cancer: a literature-based systematic HuGE review and
meta-analysis. Am J Epidem. 167:759–774. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Butkiewicz D, Grzybowska E, Phillips DH,
Hemminki K and Chorazy M: Polymorphisms of the GSTP1 and GSTM1
genes and PAH-DNA adducts in human mononuclear white blood cells.
Environ Mol Mutagen. 35:99–105. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Z, Li Z, Niu X, Yu Y, Lu S and Chen
Z: The effect of CYP1A1 polymorphism on the risk of lung cancer: a
global meta-analysis based on 71 case-control studies. Mutagenesis.
26:437–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dialyna IA, Miyakis S, Georgatou N and
Spandidos DA: Genetic polymorphisms of CYP1A1, GSTM1
and GSTT1 and lung cancer risk. Oncol Rep. 10:1829–1835.
2003.
|
|
24
|
Risch A, Wikman H, Thiel S, Schmezer P,
Edler L, Drings P, Dienemann H, Kayser K, Schulz V, Spiegelhalder B
and Bartsch H: Glutathione S-transferase M1, M3, T1 and P1
polymorphisms and susceptibility to non-small cell lung cancer
subtypes and hamartomas. Pharmacogenetics. 11:757–764. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu C, Spitz MR, Zhao H, Dong Q, Truong M,
Chang JY, Blumenschein GR Jr, Hong WK and Wu X: Association between
glutathione S-transferase pi polymorphisms and survival in patients
with advanced non-small cell lung carcinoma. Cancer. 106:441–447.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sreeja L, Syamala V, Hariharan S, Syamala
VS, Raveendran PB, Sivanandan CD, Madhavan J and Ankathil R:
Glutathione S-transferase M1, T1 and P1 polymorphisms:
susceptibility and outcome in lung cancer patients. J Exp Ther
Oncol. 7:73–85. 2008.PubMed/NCBI
|
|
27
|
Sweeney C, Nazar-Stewart V, Stapleton PL,
Eaton DL and Vaughan TL: Glutathione S-transferase M1, T1 and P1
polymorphisms and survival among lung cancer patients. Cancer Epid
Biom Prev. 12:527–533. 2003.PubMed/NCBI
|
|
28
|
Goto I, Yoneda S, Yamamoto M and Kawajiri
K: Prognostic significance of germ-line polymorphisms of the CYP1A1
and glutathione S-transferase genes in patients with non-small cell
lung cancer. Cancer Res. 56:3725–3730. 1996.PubMed/NCBI
|
|
29
|
Ada AO, Kunak CS, Hancer F, Soydas E,
Alpar S, Gulhan M and Iscan M: CYP and GST polymorphisms and
survival in advanced non-small cell lung cancer patients.
Neoplasma. 57:512–521. 2010. View Article : Google Scholar : PubMed/NCBI
|
